G1 Therapeutics, Inc.
GTHXDelisted Sep 18, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001560241
G1 Therapeutics, Inc. was delisted on Sep 18, 2024; its insiders filed their last Form 4 on Sep 18, 2024; 88 institutions reported holding it in 13F filings for Q2 2024, worth $45.5M in total; no superinvestor held it.
Q3 2021 vs. Q2 2021
How the institutions holding G1 Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 114 | 1 | 115 | +2 |
| Shares | 24.7M | 16.4K | 26.6M | +1.96M (+7.9%) |
| Value | $541.8M | $360.0K | $357.8M | −$183.7M (−33.9%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held G1 Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Russell Investments Group, Ltd. | 156,507 | $2.10M | 0.00% |
| Federated Hermes, Inc. | 60,133 | $807.0K | 0.00% |
| Ergoteles LLC | 50,767 | $681.0K | 0.03% |
| Susquehanna Fundamental Investments, LLC | 50,020 | $671.0K | 0.01% |
| ETF Managers Group, LLC | 43,446 | $647.0K | 0.01% |
| ExodusPoint Capital Management, LP | 35,174 | $472.0K | 0.01% |
| Connor, Clark & Lunn Investment Management Ltd. | 26,211 | $352.0K | 0.00% |
| Towercrest Capital Management | 17,500 | $235.0K | 0.04% |
| Franklin Resources Inc | 16,556 | $222.0K | 0.00% |
| E Fund Management Co., Ltd. | 11,607 | $156.0K | 0.01% |
| Abbot Financial Management, Inc. | 10,650 | $143.0K | 0.07% |
| Point72 Hong Kong Ltd | 6,363 | $85.0K | 0.01% |
| Allworth Financial LP | 1,262 | $17.0K | 0.00% |
| Center for Financial Planning, Inc. | 101 | $1.00K | 0.00% |
| First Horizon Advisors, Inc. | 13 | $0 | 0.00% |
Sold out (13)
Institutions that held G1 Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Point72 Asset Management, L.P. | 399,844 | $8.77M |
| PDT Partners, LLC | 51,094 | $1.12M |
| Burrage Capital Management LLC | 47,708 | $1.05M |
| Jump Financial, LLC | 33,902 | $744.0K |
| Jacobs Levy Equity Management, Inc | 10,989 | $241.0K |
| Valeo Financial Advisors, LLC | 10,646 | $234.0K |
| Principal Financial Group Inc | 9,687 | $213.0K |
| 1623 Capital LLC | 9,432 | $207.0K |
| Squarepoint Ops LLC | 9,332 | $205.0K |
| FORA Capital, LLC | 2,045 | $45.0K |
| Banque Cantonale Vaudoise | 1,500 | $33.0K |
| Advisory Services Network, LLC | 725 | $16.0K |
| Geneos Wealth Management Inc. | 300 | $6.00K |
Not filed for Q3 2021 yet (1)
Institutions that held G1 Therapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| QS Investors, LLC | 16,400 | $360.0K |